Asia Myelodysplastic Syndrome (MDS) Registry
← catalyst calendarNCT07355478 · readout in 73 d
Sponsored by Bristol-Myers Squibb (industry) · BMY — their whole pipeline →.
Phase
—
Status
Not yet recruiting
Study type
Observational
Enrollment
500estimated
Sites
3
Countries
Singapore, South Korea, Taiwan
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2026-03-26 | estimated | When the study began enrolling |
| Primary completion | 2026-10-31 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2027-09-30 | estimated | The whole study's end, after follow-up |
| First posted | 2026-01-21 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-02-13 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Myelodysplastic Syndromes (MDS)
Intervention
- Drug: Prescribed treatments for myelodysplastic syndromes (MDS)
Primary outcomes
what the primary-completion date above is the date OFParticipant age
measured Baseline
Participant sex
measured Baseline
Participant race
measured Baseline
Participant weight
measured Baseline
Participant height
measured Baseline
Participant body mass index (BMI)
measured Baseline
Participant smoking status
measured Baseline
Participant drinking status
measured Baseline
Family history of MDS or other hematopoietic cancers
measured Baseline
Participant myelodysplastic syndromes diagnosis information
measured Baseline
Participant Eastern Cooperative Oncology Group (ECOG) Performance status at diagnosis
measured Baseline
Participant comorbidities at diagnosis
measured Baseline
Participant Charlson comorbidity index (CCI) score at diagnosis
measured Baseline
Prior clinical diagnosis of other cancers
measured Baseline
Prior clinical diagnosis of hematological diseases
measured Baseline
Anemia status at diagnosis
measured Bseline
Thrombocytopenia status at diagnosis
measured Baseline
Neutropenia status at diagnosis
measured Baseline
Iron overload status at diagnosis
measured Baseline
Red blood cell (RBC) transfusion dependence status at diagnosis
measured Baseline
International Prognostic Scoring System (IPSS) score at diagnosis
measured Baseline
Revised International Prognostic Scoring System (IPSS-R) score at diagnosis
measured Baseline
Molecular International Prognostic Scoring System (IPSS-M) score at diagnosis
measured Baseline
Bone marrow aspirate results
measured Baseline and up to 2-years
Presence of dysplasia
measured Baseline and up to 2-years
Cytogenetic test results
measured Baseline and up to 2-years
Mutation test results at diagnosis
measured Baseline
Complete blood count test results at diagnosis
measured Baseline
Mean corpuscular volume (MCV)
measured Baseline and up to 2-years
C-reactive protein (CRP)
measured Baseline and up to 2-years
Serum ferritin (SF) level
measured Baseline and up to 2-years
Serum erythropoietin levels
measured Baseline and up to 2-years
Lactate dehydrogenase (LDH)
measured Baseline and up to 2-years
Permalink · BMY's whole pipeline · Catalyst calendar · Every registered study · What changed